Parallax Volatility Advisers, L.P. Biohaven Pharmaceutical Holding CO Ltd. Call Options Transaction History

Parallax Volatility Advisers, L.P.

11 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2022 Nov 14, 2022	BUY	$144.95 - $152.29 $173,940 - $182,748	1,200 New	1,200 $182,000
Q2 2021 Aug 16, 2021	SELL	$65.78 - $105.02 $4.8 Million - $7.67 Million	-73,000 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$64.07 - $91.75 $6.09 Million - $8.72 Million	-95,000 Reduced 56.55%	73,000 $4.99 Million
Q4 2020 Feb 16, 2021	SELL	$65.07 - $98.24 $10.4 Million - $15.7 Million	-159,500 Reduced 48.7%	168,000 $14.4 Million
Q3 2020 Nov 13, 2020	BUY	$59.04 - $77.95 $88,560 - $116,925	1,500 Added 0.46%	327,500 $21.3 Million
Q2 2020 Aug 14, 2020	BUY	$29.01 - $74.23 $6.27 Million - $16 Million	216,000 Added 196.36%	326,000 $23.8 Million
Q1 2020 May 15, 2020	BUY	$27.51 - $57.29 $591,465 - $1.23 Million	21,500 Added 24.29%	110,000 $3.74 Million
Q1 2019 May 15, 2019	BUY	$34.52 - $53.29 $2.33 Million - $3.6 Million	67,500 Added 321.43%	88,500 $4.56 Million
Q4 2018 Feb 14, 2019	BUY	$29.75 - $42.9 $624,750 - $900,900	21,000 New	21,000 $777,000
Q2 2018 Aug 14, 2018	SELL	$23.62 - $42.29 $803,080 - $1.44 Million	-34,000 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$22.49 - $34.56 $764,660 - $1.18 Million	34,000 New	34,000 $876,000

785K

Ticker BHVN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,645,000
Market Cap $3.65B
Description
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...

Get notified when there are updates to the investment portfolio of Parallax Volatility Advisers, L.P., based on Form 13F filings with the SEC.

Stay updated on Parallax Volatility Advisers, L.P. with notifications on news.